News and Announcements
RISKflo Announced a 5-year Contract with a Major Financial Services Company
- Published May 19, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
RISKflo, a multi-stakeholder collaborative review, approval, monitoring, and reporting platform announced a renewal of a major International Bank contract – of 5 years (3+1+1). The bank confirmed its commitment to RISKflo as a best-in-class provider of third-party risk management (TPRM) solutions to the financial services industry.
The latest renewal will give RISKflo over 10 years of connection to this major financial service group. It has enabled RISKflo additional development and deployment of a world-leading platform which is a “no-code” highly flexible business solution. The major client intends to extend the usage of the RISKflo platform and apply SmartScripts™ to different business entities beyond banking, including but not limited to their insurance businesses. In support of this direction, RISKflo has moved to a user-pays pricing model and removed all previous contract-based technical and commercial constraints. This essentially extends to the client the unfettered ability to create ‘Super’ SmartScripts™ for any use case and will be managed by the client by their internal team.
Regulatory Compliance is one of the biggest issues facing Financial Institutions today. With over 200 regulators, financial institutions are faced with new regulations, on average, every 3 minutes.
Unfortunately, existing automation solutions are not built to facilitate the deployment of this sort of change to regulations and policy in a large complex financial institution. By comparison, RISKflo provides third-party risk and compliance solutions across 19 countries in the Asia Pacific. The RISKflo solution recently allowed the bank to complete remediation of third parties required by the regulator to be completed in 2-3 days compared to 3-6 months previously.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
